Auro Laboratories Ltd530233Corporate

Pharmaceuticals Latest results: Sep 2025 3 quarters of data

₹247.90

MCap ₹154 Cr

Auro Laboratories Ltd — Stock analysis & AI research Auro Laboratories Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹9 Cr

Sales · Sep 2025

+185.2% YoY

₹2 Cr

Operating Profit · Sep 2025

+226.4% YoY

26.6%

OPM % · Sep 2025

+14.7% YoY

₹1 Cr

Net Profit · Sep 2025

+100.0% YoY

₹1.16

EPS · Sep 2025

+100.0% YoY

📝 Auro Laboratories Ltd — results explained

Quarter ended September 2025 (Q2 FY26)

Auro Laboratories Ltd reported revenue of ₹9 crore for the quarter ended September 2025 (Q2 FY26), up 185.2% from ₹3 crore in the same quarter last year, and up 219.1% sequentially over the June 2025 quarter.

Net profit rose 100.0% year-on-year to ₹1 crore, from ₹0 crore. Earnings per share (EPS) came in at ₹1.16.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 26.6%, compared with 23.2% in the year-ago quarter.

Valuation snapshot

At the current price of ₹247.90, 530233 has a market capitalisation of ₹154 crore.

Within the Pharmaceuticals industry, it is the 25th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 52.17%, domestic institutional investors (DIIs) 0.01%, public shareholders 47.82% of Auro Laboratories Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹154 Cr

Current Price ?

₹247.9

P/E ?

N/A

Industry P/E ?

22.40

P/B ?

3.54

P/S ?

N/A

P/FCF ?

-11.84

Enterprise Value ?

₹198 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹9 Cr

PAT — latest qtr ?

₹1 Cr

YoY qtr sales growth ?

185.2%

YoY qtr profit growth ?

100.0%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹44 Cr

Debt to Equity ?

1.01

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

52.17%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-4.8%

Return 6 months ?

-11.1%

🗓️ Quarterly results (3 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2024	Jun 2025	Sep 2025	YoY %	QoQ %
Sales	3	3	9	+185.2%	+219.1%
Operating Profit	1	0	2	+226.4%	+7733.3%
Other Income	0	0	1	+216.1%	+133.3%
Interest	0	0	1	+242.9%	+242.9%
Depreciation	0	0	1	+140.7%	+140.7%
Profit Before Tax	0	-0	2	+258.3%	+1820.0%
Net Profit	0	-0	1	+100.0%	+754.5%
EPS	0.58	-0.18	1.16	+100.0%	+744.4%
OPM %	23.2%	1.1%	26.6%	+14.7%	+2318.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 2 periods)

Metric	Mar 2025	Sep 2025	% Chg
Equity Capital	6.23	6.23	+0.0%
Reserves	36.74	37.35	+1.7%
Borrowings	42.72	43.94	+2.9%
Other Liabilities	13.41	23.25	+73.4%
Total Liabilities	99.10	110.77	+11.8%
Fixed Assets	21.05	76.84	+265.0%
CWIP	56.48	10.37	-81.6%
Investments	0.05	0.05	+0.0%
Other Assets	21.52	23.51	+9.2%
Total Assets	99.10	110.77	+11.8%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	3.28	18.81	5.75	2.11	-63.3%
Cash from Investing Activity	-5.08	-38.67	-24.45	-14.78	+39.6%
Cash from Financing Activity	-8.18	19.09	17.69	14.04	-20.6%
Net Cash Flow	-9.98	-0.77	-1.02	1.37	+234.3%
Free Cash Flow	-0.79	18.81	5.75	-13.04	-326.8%
CFO/OP	75%	176%	169%	21%	-87.6%

➗ Ratios (latest 1 periods)

Metric	Mar 2025	% Chg
Debtor Days	176.67	—
Inventory Days	145.45	—
Days Payable	246.11	—
Cash Conversion Cycle	76.01	—
Working Capital Days	-14.30	—

👥 Shareholding (latest 4 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	% Chg
Promoters	52.17%	52.17%	52.17%	52.17%	+0.0%
DIIs	0.01%	0.01%	0.01%	0.01%	+0.0%
Public	47.82%	47.82%	47.80%	47.82%	+0.0%
No. of Shareholders	8,916	8,860	8,640	8,405	-2.7%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUDEEPPHRM Sudeep Pharma	₹1,033.30	11,671	63.3	675	184	34.6%	27.3%	—	—	26.6%	30.9%
2	SPARC Sun Pharma	₹185.08	6,006	3.8	1,909	1,584	84.7%	83.0%	2512.3%	553.9%	314.1%	59.9%
3	GUJTHEM Gujarat Themis	₹412.60	5,370	92.3	173	48	47.3%	27.8%	8.6%	-6.1%	21.6%	23.0%
4	539997 Kwality Pharmaceuticals	₹2,652.10	3,525	34.0	553	81	24.4%	14.6%	35.7%	71.8%	46.3%	113.5%
5	524632 Shukra Pharmaceuticals	₹80.95	2,403	99.9	75	36	65.0%	48.2%	74.0%	130.1%	336.4%	1359.2%
6	FERMENTA Fermenta Biotech	₹475.00	1,362	21.4	501	64	18.9%	12.7%	—	—	-17.9%	-30.6%
7	506414 Fermenta Biotech	₹552.60	1,313	27.2	511	59	17.6%	11.5%	11.9%	-6.6%	-10.4%	-56.7%
8	AHCL Anlon Healthcare	₹20.20	1,074	—	—	—	—	—	—	—	163.0%	133.3%
9	541096 Bharat Parenterals	₹1,525.00	1,062	—	323	-30	3.3%	-9.3%	1.5%	37.5%	-19.2%	-309.6%
10	540737 Shree Ganesh	₹796.30	855	66.2	99	15	31.4%	15.6%	0.7%	-23.0%	-41.8%	-67.5%
11	AMANTA Amanta Healthcare	₹197.75	768	52.5	291	15	20.4%	5.0%	—	—	5.4%	-5.6%
12	539730 Fredun Pharmaceuticals	₹827.85	611	10.3	747	44	14.7%	5.9%	40.1%	90.0%	90.2%	88.1%
13	500422 Transchem Ltd-$	₹38.00	474	10.8	—	4	—	—	-100.0%	-17.8%	-100.0%	186.3%
14	HALEOSLABS Haleos Labs	₹1,525.00	461	21.0	324	15	12.6%	4.7%	-3.2%	-4.9%	-11.6%	-58.0%
15	524731 Jenburkt Pharmaceuticals	₹865.75	404	11.6	170	33	23.6%	19.4%	11.8%	6.1%	-1.4%	-26.4%
16	543616 Trident Lifeline	₹279.85	364	14.0	134	24	24.6%	17.9%	—	—	42.6%	44.2%
17	512600 Astal Laboratories	₹75.00	308	32.3	170	10	8.8%	5.7%	142.9%	-9.0%	56.0%	77.4%
18	524828 BDH Industries	₹336.80	300	16.6	100	12	15.3%	11.7%	44.3%	16.6%	20.2%	48.8%
19	500009 Ambalal Sarabhai	₹38.73	297	21.9	206	14	7.1%	6.6%	3.1%	261.1%	8.0%	-51.6%
20	532039 Zenotech Laboratories	₹64.90	263	—	45	-3	17.0%	-5.6%	1.3%	-119.2%	10.1%	-146.0%
21	531739 Gennex Laboratories	₹13.87	255	19.0	183	21	14.4%	11.3%	24.9%	15.5%	16.6%	-6.9%
22	524790 Everest Organics	₹159.20	252	29.4	191	5	10.3%	2.8%	23.0%	527.7%	-10.0%	-21.1%
23	530163 Kerala Ayurveda	₹310.20	225	—	125	-26	-14.9%	-20.8%	9.0%	-16.8%	-21.3%	-477.8%
24	531569 Sanjivani Paranteral	₹199.95	214	32.7	66	7	15.3%	11.3%	-7.6%	-14.4%	8.8%	32.7%
25	530233 Auro Laboratories	₹176.85	154	23.5	37	5	35.4%	12.7%	60.0%	127.7%	216.5%	1050.5%

❓ Frequently asked questions

What was Auro Laboratories Ltd's revenue in Q2 FY26?

What was Auro Laboratories Ltd's net profit in Q2 FY26?